Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from MRNA

Moderna Stock Rises After FDA Application For Updated Vaccine

Moderna's potential beyond COVID-19 is underappreciated, says analyst Eliana Merle, who upgraded the stock to Buy

Zenger

Moderna (MRNA) vs. BioNTech (BNTX): Which Biotech Stock Should You Be Investing In?

Amidst the biotech industry’s rapid growth and notable advancements, let’s analyze which of the two major players, Moderna (MRNA) and BioNTech (BNTX), is a more favorable investment choice in the current uncertain economic climate. Keep reading to find out.

StockNews.com

Buy, Hold or Sell? Gilead Sciences Inc. (GILD) and Moderna Inc. (MRNA)

Rapid breakthroughs and surging demand position the biotech sector for significant expansion in the near term. Therefore, quality biotech stock Gilead Sciences (GILD) could be worth buying. However, I think it will be best to wait for a better entry point in Moderna (MRNA). Read on.

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

Moderna Stock Pops on Surprise Earnings Beat

An unexpected profit and promising news on a deal with the EU boosted Moderna stock.

Kiplinger

Bearish Option Trade For MRNA Stock

With low implied volatility right now, a bear put spread on Moderna is a viable strategy to profit on the downside.

Investors Business Daily

Investing Champion Leif Soreide Notes Biotech Stocks May Be Countercyclical

Biotech stocks can often be countercyclical, according to some market experts. We explore some biotech opportunities in this article.

StockNews.com

Dow Jones Futures Rise, Tesla Bounces After Leading Growth Sell-Off; 5 Stocks Near Buy Points

Tesla bounced early after leading a growth sell-off with Moderna and Nvidia. Many industrial and energy plays are thriving

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

2 Biotech Stock to Buy Over Moderna This December

Biotech giant Moderna (MRNA) missed consensus revenue and EPS estimates in its 2022 third quarter. Moreover, it lost more than 17% in 2022. While analysts are bearish on MRNA’s growth, the industry prospects look bright. Therefore, investors looking to invest in biotech stocks could consider buying Biogen (BIIB) and Jazz…

StockNews.com

Check Out What Whales Are Doing With MRNA

Someone with a lot of money to spend has taken a bullish stance on Moderna (NASDAQ:MRNA). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

This Is What Whales Are Betting On Moderna

Someone with a lot of money to spend has taken a bearish stance on Moderna (NASDAQ:MRNA). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Moderna Unusual Options Activity

A whale with a lot of money to spend has taken a noticeably bearish stance on Moderna. Looking at options history for Moderna (NASDAQ:MRNA) we detected 17 strange trades.

Benzinga

Pfizer Quadruples Its Covid Shot Price — And Other Vaccine Stocks Rocket

Moderna snagged an upgrade Friday on views it will hike charges for its Covid vaccine, as Pfizer plans to charge up to $130 for its shot.

Investors Business Daily

Moderna Stock Fails At Declining 50-Day Average; Check Out This Bearish Option Play

Traders who think Moderna stock will not reclaim the 50-day line could look at a bear call spread at 145-150.

Investors Business Daily

Check Out What Whales Are Doing With MRNA

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Check Out What Whales Are Doing With MRNA

A whale with a lot of money to spend has taken a noticeably bearish stance on Moderna. Looking at options history for Moderna (NASDAQ:MRNA) we detected 26 strange trades.

Benzinga

Moderna Rallies On Merck Collaboration: Can Drugmaker Replace COVID Vaccine Revenue?

In late 2020, when the world was searching for a vaccine or cure for COVID-19, the price action in Moderna Inc (NASDAQ: MRNA) was discussed frequently on Benzinga's PreMarket Prep show.

Investors Business Daily

Moderna Surges As Merck Inks Deal To Co-Develop Personalized Cancer Vaccine Treatment

Merck opted Wednesday to help Moderna develop a personalized cancer vaccine based on messenger RNA technology, and MRNA stock rocketed.

Benzinga

Looking At Moderna's Recent Whale Trades

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Check Out What Whales Are Doing With MRNA

Benzinga

This Is What Whales Are Betting On Moderna

A whale with a lot of money to spend has taken a noticeably bearish stance on Moderna. Looking at options history for Moderna (NASDAQ:MRNA) we detected 25 strange trades.

Benzinga

10 Health Care Stocks Whale Activity In Today's Session

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.

Benzinga

Check Out What Whales Are Doing With MRNA

Benzinga

Check Out What Whales Are Doing With MRNA

A whale with a lot of money to spend has taken a noticeably bearish stance on Moderna. Looking at options history for Moderna (NASDAQ:MRNA) we detected 35 strange trades.

Benzinga

Check Out What Whales Are Doing With MRNA

A whale with a lot of money to spend has taken a noticeably bearish stance on Moderna. Looking at options history for Moderna (NASDAQ:MRNA) we detected 20 strange trades.

Benzinga

This Is What Whales Are Betting On Moderna

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

SP Global Market Intelligence

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.